Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PSNL vs NDRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PSNL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)
PSNL Overall Winner
6-Pillar Tally: PSNL 4 – 1 NDRA (1 Tie)
Matrix Metrics: PSNL 5 – 3 NDRA
As of Nov 16, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). PSNL carries a Unified Composite Score of 33.0/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PSNL 33.0/100 SELL), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. 0.0% operating margin) and revenue trajectory (+76.6% vs. +0.0% YoY).
- Technical & Structure Timing Caution: PSNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PSNL vs NDRA
PSNL
Head-to-Head Winner
Personalis, Inc. Common Stock
$14.80
-5.79% 1D
Market Cap
$1.7B
TTM Revenue
$81M
Forward P/E
N/M
Beta / 30D Vol
1.86β · 21% Vol
Unified Composite Score
33.0
SELL
Tech 9.0
Fund 48.0
Flow 58.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
NDRA
ENDRA Life Sciences Inc. Common Stock
$4.42
+0.23% 1D
Market Cap
$6.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.71β · 48% Vol
Unified Composite Score
44.7
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PSNL 4 – 1 NDRA)
1. Valuation Multiples
PSNL
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
20.3x
N/M
2. Growth & Scale
PSNL
Revenue Growth (YoY)
+76.6%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$81M
N/A
Market Cap
$1.7B
$6.6M
3. Profitability & Quality
NDRA
Gross Margin
16.7%
N/A
Operating Margin
-156.7%
0.0%
Net Profit Margin
-147.7%
0.0%
Return on Equity (ROE)
-62.1%
-152.0%
4. Balance Sheet & Cash Flow
PSNL
Cash Generation (TTM)
-$108M
-$8.0M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$61M Net Cash
$104,744 Net Debt (0.26x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PSNL
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
35.2% (2nd %ile)
N/A (N/A)
Put/Call OI Skew
0.02x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PSNL (5) vs NDRA (3)| Institutional Metric | PSNL | NDRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.7B | $6.6M | PSNL | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +76.6% | +0.0% | PSNL | |
| Operating Margin (TTM) | -156.7% | 0.0% | NDRA | |
| Net Profit Margin | -147.7% | 0.0% | NDRA | |
| Return on Equity (ROE) | -62.1% | -152.0% | PSNL | |
| 52-Week Range Position | 71% ($5–$19) | 37% ($3–$7) | PSNL | |
| Beta / 30D Volatility | 1.86β · 21% Vol | 0.71β · 48% Vol | PSNL | |
| Unified Institutional Score | 33.0 / 100 (SELL) | 44.7 / 100 (HOLD) | NDRA | |
| Trailing 12M Revenue (USD) | $81M | N/A | Scale | |
| Gross Profit Margin (TTM) | 16.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 20.3x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$108M ($61M Net Cash) | -$8.0M ($104,744 Net Debt (0.26x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PSNL +1.32 pp
3M Horizon
PSNL +8.4 pp
6M Horizon
PSNL +138.54 pp
1Y Horizon
PSNL +127.46 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PSNL Revenue | NDRA Revenue | PSNL Op. Margin | NDRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $40M | $0M | -36.5% | -146080.5% | PSNL |
| FY2019 | $70M | N/A | -34.4% | N/A | PSNL |
| FY2020 | $80M | N/A | -53.6% | N/A | PSNL |
| FY2021 | $90M | N/A | -76.4% | N/A | PSNL |
| FY2022 | $70M | N/A | -177.6% | N/A | PSNL |
| FY2023 | $70M | N/A | -149.6% | N/A | PSNL |
| FY2024 | $80M | N/A | -80.7% | N/A | PSNL |
| FY2025 | $70M | N/A | -126.4% | N/A | PSNL |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PSNL
CONSOLIDATION
Current IV
35.2%
IV Percentile
2nd %ile
Put/Call OI Skew
0.02x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact PSNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NDRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PSNL Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
NDRA Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PSNL vs NDRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). PSNL carries a Unified Composite Score of 33.0/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PSNL 33.0/100 SELL), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. 0.0% operating margin) and revenue trajectory (+76.6% vs. +0.0% YoY). Technical & Structure Timing Caution: PSNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PSNL leads the Growth & Scale pillar: PSNL posts +76.6% YoY revenue growth and +0.0% YoY earnings growth on $81M TTM revenue (16.7% gross margin, -156.7% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PSNL cumulative revenue shifted +75.0% while NDRA shifted N/A. In operating R&D and SG&A reinvestment, PSNL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.
PSNL screens cheaper on headline valuation multiples. PSNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 20.3x EV/Revenue (unreported FCF margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PSNL (-62.1% ROE) versus NDRA (-152.0% ROE) capital efficiency.
In options market volatility and institutional positioning, PSNL carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.86β · 21% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NDRA vs PSNL · Reverse Pair
PSNL vs CDNA
· Sector Peer
PSNL vs TWST
· Sector Peer
PSNL vs VCYT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking